N.B. DRUZHKOVA^1,2, Z.A. AFANASIEVA^1,2

¹Kazan State Medical Academy — Branch Campus of  RMACPE MH Russia, Kazan

²Tatarstan Cancer Center, Kazan

 Contact:

Druzhkova N.B. — postgraduate student of the Endocrinology Department, endocrinologist

Address: 36 Butlerov Str., Kazan, Russian Federation, 420012, e-mail: n.b.druzhkova@mail.ru

 The article presents a clinical case of successful conservative treatment of severe hypercalcemia in a young patient, which developed due to metastatic parathyroid cancer. The clinical observation illustrates successful application of cinacalcetum and denosumab for treating severe hypercalcemia in a patient with metastatic parathyroid cancer.

Key words: hypercalcemia, hypercalcemic crisis, primary hyperparathyroidism, parathyroid cancer.

REFERENCES

1. Walsh J., Gittoes N., Selby P. Society for Endocrinology Clinical Committee. Society For Endocrinology Endocrine Emergency Guidance: Emergency management of acute hypercalcaemia in adult patients. Endocr. Connect, 2016, no. 5 (5), pp. G9-G11.
2. Goltzman D. Nonparathyroid Hypercalcemia / Brandi M.L. (ed): Parathyroid Disorders. Focusing on Unmet Needs. Front. Horm. Res. Basel, Karger, 2019, vol. 51, pp. 77-90.
3. Dedov I.I., Mel’nichenko G.A., Mokrysheva N.G. et al. Primary hyperparathyroidism: clinical features, diagnosis, differential diagnosis, treatment methods. Problemy endokrinologii, 2016, no. 6, pp. 40-77 (in Russ.).
4. Ahmad S., Kuraganti G., Steenkamp D. Hypercalcemic crisis: a clinical review. The American Journal of Medicine, 2015, vol. 128, no. 3, pp. 239-245.
5. Al-Kurd A., Mekel M., Mazeh H. Parathyroid carcinoma. Surg. Oncol, 2014, no. 23 (2), pp. 107-14.
6. Basso S.M., Lumachi F., Nascimben F. et al. Treatment of acute hypercalcemia. Med. Chem, 2012, no. 8 (4), pp. 564-568.
7. Ziegler R. Hypercalcemia Crisis. J. Am. Soc. Nephrol, 2001, no. 12, pp. 53-59.
8. Carroll M., Schade D. A Practical Approach to Hypercalcemia. Am. Fam. Physician, 2003, no. 67 (9), pp. 1959-66.
9. Schulte K-M., Talat N. Diagnosis and management of parathyroid cancer. Nat. rev Endocrinol, 2012, no. 8, pp. 612-22.
10. Sternlicht H., Glezerman I.G. Hypercalcemia of malignancy and new treatment options. Ther. Clin. Risk Manag, 2015, no. 11, pp. 1779-88.
11. Betea D., Potorac I., Beckers A. Parathyroid carcinoma: Challenges in diagnosis and treatment. Ann. Endocrinol (Paris), 2015, no. 76 (2), pp. 169-77.
12. Vellanki P., Lange K., Elaraj D. et al. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J. Clin. Endocrinol. Metab, 2014, no. 99 (2), pp. 387-90.
13. Fountas A., Andrikoula M., Giotaki Z. The emerging role of denosumab in the long-term management of parathyroidcarcinoma-related refractory hypercalcemia. Endocr. Pract, 2015, no. 21 (5), pp. 468-73.
14. Castellano D., Sepulveda J.M., García-Escobar I. et al. The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab. The Oncologist, 2011, no. 16, pp. 136-145.
15. Silverberg S.J., Rubin M.R., Faiman C. et al. Cinaclcet hydrochloride reduces the serum calcium concentrations in inoperable parathyroid carcinoma. J. Clin. Endocrinol. Metab, 2007, no. 92, pp. 3803-3808.
16. Betea D., Bradwell A.R., Harvey T.C. et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J. Clin. Endocrinol. Metab, 2004, no. 89, pp. 3413-20.
17. Horie I., Ando T., Inokuchi N. et al. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma. Endocr. J, 2010, no. 57, pp. 287-92.
18. Gorbunova V.A., Pigarova E.A., Rozhinskaya L.Ya. et al. Use of sorafenib (nexavar) in the treatment of a patient with disseminated parathyroid cancer (clinical case). Opukholi golovy i shei, 2016, vol. 6, no. 4, pp. 67-72 (in Russ.).